This invention relates to the field of recombinant 
antibody technology. It provides novel recombinant IgY 
antibody constructs for diagnostic and therapeutical applications. The bivalent 
antibody constructs display a heterotetrameric or homodimeric format stabilized by disulfide bonds. The constant 
heavy chain domains CH2-CH4 are partly or completely of avian origin, whereas the VH, VL, CL, and CH1 domains as well as the 
hinge region may be of avian origin or derived from any other species. The invention allows to combine the advantages of IgY antibodies with those of established mammalian 
monoclonal antibodies. IgY antibody constructs comprising nonglycosylated IgY constant 
heavy chain domains allow to reduce unwanted interactions with C-type lectins, e.g., in human sera. Furthermore, chimeric IgY antibody containing mammalian VH, VL, CL, and CH1 domains as well as a mammalian 
hinge region provide a higher 
molecular stability than IgY antibodies in acidic conditions and, thereby, are especially suited for peroral therapeutic applications.